RE: Edison Investment Research Article2 Oct 2021 09:22
I liked this bit ;
''although QDs were first used as biological probes in 1998, the technique is still not widely adopted because of concerns about heavy metal toxicity (see below). We note that initial trials by a third party on Nanoco’s VIVODOT QDs, which are cadmium free, have passed initial toxicology tests which found no evidence of mutagenicity. VIVODOT QDs completed the proof-of-concept stage in a project conjugating them with antibodies to detect cancer. They are currently being used in an 18-month project, which started in November 2020 to detect COVID-19 antibodies which could potentially form the basis of an accurate and, pid self-administered test with results produced in situ.''